The CyPass Micro-Stent, designed as a minimally invasive device to decrease intraocular pressure in glaucoma patients, is being tested in over 20 locations in the US and has been utilized in over 500 glaucoma patients receiving cataract surgery.
Transcend Medical has completed enrollment for the COMPASS study. Transcend Medical and the participants of COMPASS hope to soon bring the CyPass Micro-Stent to the FDA for approval.
More Articles on Ophthalmology:
Ocular Therapeutix Seeking FDA Approval for ReSure Sealant
TearScience Receives $70M in Funding
6 New Ophthalmology-Driven Facilities
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.